33 C
Vientiane
Friday, May 2, 2025
spot_img
Home Blog Page 549

Finit sells Data to Major Hedge Fund, Expanding Beyond Their B2C Platform Business

Improving inefficiencies can lead to business opportunities 

VIENNA, Va., Feb. 19, 2025 /PRNewswire/ — When an improved method provides value, customers are willing to pay for it.  Finit Co., Ltd., which developed order flow analytics and expanded to the U.S. market through its subsidiary, TradePulse Technologies, Inc., recently sold its Korean stock flow data to a major U.S. top tier high-frequency/ algorithmic trading hedge fund. With its AI-inferred proprietary algorithm, Finit developed major solutions for two separate markets.

  • PowerMap (for Korean stocks)
  • TradePulse (for U.S. stocks)

Their core technology analyzes real-time trading patterns to predict stock trend reversals using AI trained on 15 years of historical data. Currently, the AI utilizes hundreds of thousands of trade patterns to forecast stock movements. For instance, if someone buys 100 shares of Samsung Electronics every minute for two hours, combining this with other characteristics, the system can infer which foreign brokerage is making the purchase. With AI-driven pattern analysis, feature detection, and inference engines, Finit processes hundreds of thousands of trade signals in real time.

In the Korean stock market, investors often wonder who (foreign investors, institutions, or individuals) is buying or selling stocks when making trading decisions. While brokerage trading platforms provide categorized transaction data, they are typically delayed until after 6 PM, well after the market has closed. Only after the market has closed, brokerage firms manually input trading data for foreign investors and institutions. With Finit‘s PowerMap integrated into Korean brokerage apps, users can see real-time predictive trading volumes by category.

With experts capable of implementing Direct Market Access (DMA) and High-Frequency Trading (HFT) technology, Finit was able to develop the PowerMap which processes and delivers large-scale transactions in real time. Processing large volumes of stock transactions instantly requires powerful data processing capabilities. Finit receives direct trade data from exchanges and analyzes buy and sell signals for approximately 1,000 stocks in real time (covering KOSPI stocks with a market cap over 200 billion KRW ($133.38 M) and KOSDAQ stocks over 150 billion KRW ($103.81 M) .

Currently, Finit‘s service PoweMap is available through Korean brokerage apps. However, the company aims to expand to U.S. retail investors, signing contracts with Interactive Brokers, Tradier Brokerage, Quasar Markets, and Cobra Trading to develop tailored solutions such as TradePulse for American investors.

Traditional trading indicators often fail to capture the true market dynamics, relying heavily on past price movements rather than real-time transaction flows. This creates blind spots, especially in fast-moving markets where institutional orders and algorithmic trades can drastically shift stock prices. By processing vast amounts of stock transaction data at high speed and applying AI-driven inference models, TradePulse eliminates these gaps, providing both institutional and retail traders with order flow data in real time, accurately identifying market orders and volumes.

TradePulse, a leading provider of innovative order flow analytics through its proprietary AI-driven algorithm, analyzes over 4,000 U.S. stocks, including Apple, Microsoft, NVIDIA, and Amazon.

“Unlike Korea, U.S. exchanges do not categorize trading data by foreign and institutional investors. Instead, we developed indicators such as large trade volume and buy intensity to predict stock trends.”

For example, if buy intensity and large transactions increase simultaneously within a minute, there is an 84% chance the stock price will rise within three minutes.

Although stock prices may only rise by an average of 1.2% per day, and accuracy is not 100%, TradePulse provides investors with an additional key metric for decision-making.

**About TradePulse**

TradePulse Technologies, Inc. is a leading provider of innovative trading solutions, specializing in order flow analytics. With eight partner companies and no lost partnerships, TradePulse’s technology is highly trusted. The company boasts 2 million page views per day and serves 400,000 users, underscoring its significant market presence and the value it provides to investors.

X | LinkedIn

Tribesigns Ushers in New Era with Newly Updated Logo

NEW YORK, Feb. 19, 2025 /PRNewswire/ — Tribesigns, a globally renowned furniture manufacturer and retailer offering cozy and efficient home and office solutions for every home, is thrilled to announce the debut of its newly redesigned logo, launching on Feb 24th, 2025.

New Logo.
New Logo.

The new logo is an innovative blend of the tent element of primitive tribes and the letter “T”. It is rendered in a geometric design using a flat, planar structure composed of line. Its flat and linear structure creatively symbolizes a blend of a table and a house, reflecting the brand’s core theme of “home.”

Logo Philosophy
Logo Philosophy

Tribesigns’ diverse product portfolio spans multiple furniture categories, including kids’, pet, and office furniture. The updated logo will serve as a shared and symbolic element across all Tribesigns sub-brands, reinforcing the brand’s cohesive identity. 

“This new logo will be widely used in all kinds of Tribesigns brand activities in various channels such as social media, official websites, and e-commerce platforms such Amazon, Walmart, and Wayfair,” said Sophia Zhao, the Chief Product Officer of Tribesigns.

With “Designed for Life” as its slogan, Tribesigns will maintain its commitment to delivering top-tier, unique and innovative home and office solutions worldwide.

Tribesigns offers a comprehensive furniture solution for households and businesses, including the living room, bedroom, home office, hallway, kitchen and dining room. Besides, it has provided various indoor and outdoor furniture products to over 30 million households in the U.S., Canada, Europe and Australia in the past 14 years.

About Tribesigns

Tribesigns is a leading global furniture designer and manufacturer. With the slogan ‘Designed For Life’, its philosophy revolves around the diversity of personal lifestyles and the importance of embracing nature-friendly choices. 

Tribesigns is also widely known for its special and elegant furniture designs, most of its newest models are unique in the market and cannot be found elsewhere, and you will never be disappointed when you choose Tribesigns. With more than 35 overseas warehouses, strong R&D and manufacturing capacities, Tribesigns also offers dropshipping, OEM, and ODM services for business partners

For more information about Tribesigns, please visit https://tribesigns.com/AmazonB2BFacebook,  InstagramYouTubePinterest and TikTok.

Nisun International Partners with Gold of China to Expand Gold Business, Targeting $30-$50 Million in Sales Growth from Venture in 2025

SHANGHAI, Feb. 19, 2025 /PRNewswire/ — Nisun International Enterprise Development Group Co., Ltd (“Nisun International” or the “Company”) (Nasdaq: NISN), a technology and industry driven integrated supply chain solutions provider, today announced a strategic partnership with Gold of China Co., Ltd. (中银金行) (“Gold of China“), a national leader in the gold industry, to expand its gold business segment. This collaboration leverages soaring gold prices and growing market demand, positioning Nisun International to grow its footprint in both the gold retail and wholesale sectors. The projected sales are estimated to be between $30 to $50 million for 2025.

Amid a dynamic global economic landscape, gold has solidified its status as a premier safe-haven asset. In 2025, gold prices have surged to their eighth record high this year, climbing nearly 11% year-to-date following a remarkable 27% increase in 2024. This upward trajectory, driven by gold’s unique commodity, financial, currency, and hedging attributes, has sparked widespread interest from investors worldwide. Against this backdrop, Nisun International is seizing the moment to capitalize on the booming gold market through its alliance with Gold of China, a respected corporation founded in 1992 and approved by the People’s Bank of China (stock code: 871846).

A Comprehensive Gold Industry Platform

The partnership unites Nisun International’s robust supply chain management capabilities with Gold of China’s expertise as one of China’s few national enterprises historically specializing in gold jewelry, both wholesale and retail. Together, the companies are building a comprehensive gold service platform spanning the entire industry chain. Key initiatives include:

  • Centralized Procurement: Nisun International is optimizing procurement processes to ensure reliable, cost-effective gold sourcing, enhancing operational efficiency.
  • Retail Innovation: With rising demand for investment gold bars and other products, Nisun International is introducing innovative marketing strategies and improving customer experiences to meet diverse consumer needs.
  • Wholesale Expansion: The collaboration aims to scale wholesale operations, leveraging Gold of China’s established industry presence.

This multi-faceted approach is designed to strengthen Nisun International’s competitive edge while delivering high-quality gold products and services to both investors and consumers.

Management Commentary

Xin Liu, Chief Executive Officer of Nisun International, commented:
“The gold market’s unprecedented growth presents a transformative opportunity for Nisun International. Our partnership with Gold of China positions us to harness this momentum, expanding our gold business across all channels. We expect this venture to drive significant growth, potentially adding $30 to $50 million in sales in 2025, while reinforcing our commitment to creating value for our stakeholders and customers.”

Market Reception and Future Outlook

Nisun International’s strategic push into the gold industry has already garnered positive market recognition, underscoring the Company’s ability to adapt to evolving economic trends. Looking ahead, Nisun International plans to deepen its collaboration with Gold of China and other strategic partners, exploring new opportunities to innovate within the gold sector and deliver long-term value.

About Nisun International Enterprise Development Group Co., Ltd

Nisun International Enterprise Development Group Co., Ltd (NASDAQ: NISN) is a technology-driven, integrated supply chain solutions provider focused on transforming the corporate finance industry. Leveraging its industry experience, Nisun International is dedicated to providing professional supply chain solutions to Chinese and foreign enterprises and financial institutions. Through its subsidiaries, Nisun International provides users with professional solutions for technology supply chain management, technology asset routing, and digital transformation of tech and finance institutions, enabling the industry to strengthen and grow. At the same time, Nisun International continues to deepen the field of industry segmentation through industrial and financial integration. Focusing on industry-finance linkages, Nisun International aims to serve the upstream and downstream of the industrial supply chain while also assisting with supply-side sub-sector reform. For more information, please visit http://ir.nisun-international.com/

Cautionary Note Regarding Forward-Looking Statements

This press release contains information about Nisun International ‘s view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. Nisun International encourages you to review other factors that may affect its future results in Nisun International ‘s registration statement and in its other filings with the Securities and Exchange Commission. Nisun International assumes no obligation to update or revise its forward-looking statements as a result of new information, future events or otherwise, except as expressly required by applicable law.

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA

SYDNEY, Feb. 19, 2025 /PRNewswire/ — Clarity Pharmaceuticals (ASX: CU6) (“Clarity” or “Company”), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the United States (US) Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) for 67Cu-SAR-bisPSMA for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with androgen receptor pathway inhibition (ARPI).

This milestone builds on Clarity’s earlier receipt of 2 FTDs for the diagnostic 64Cu-SAR-bisPSMA in patients with suspected metastasis of prostate cancer who are candidates for initial definitive therapy[1], as well as patients with biochemical recurrence (BCR) of prostate cancer following definitive therapy[2], with 2 Phase III registration trials underway (CLARIFY [NCT06056830][3] and AMPLIFY, respectively). These 3 FTDs demonstrate the quality of the data generated to date on the 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA products in addressing serious unmet needs in prostate cancer. The FTDs will enable Clarity to accelerate the development of its comprehensive program with the optimised SAR-bisPSMA agent to be used in patients with prostate cancer throughout the management of their cancer, from initial to late-stage disease, with an opportunity to completely change the entire treatment landscape for the large prostate cancer market.

The FDA’s FTD is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs. For SAR-bisPSMA, it provides a number of product development advantages. The designations pave the way for a faster review process once Clarity submits its product approval applications. Additionally, it enables more frequent communication with the FDA, allowing for rapid resolution of queries during development. Furthermore, Clarity can submit completed sections of its application as they are ready, rather than waiting for the entire package to be finished before it can be lodged with the FDA. These benefits would reduce the review time needed to bring this innovative and proprietary molecule to the prostate cancer imaging and therapy markets.

The data for this FTD submission was based on the preliminary results to date from the Phase I/IIa SECuRE study (NCT04868604)[4], which is investigating the safety and efficacy of 67Cu-SAR-bisPSMA for the treatment of mCRPC patients. The first 3 cohorts in the dose escalation phase of the trial were successfully completed with no dose limiting toxicities (DLTs) reported in any of the participants dosed (15 participants). No adverse events (AEs) related to 64Cu-SAR-bisPSMA were observed. Most AEs related to 67Cu-SAR-bisPSMA were low grade (grade 1 or 2). The most common AE reported was mild dry mouth (grade 1, 5/15 participants, 33.3%).

Preliminary data shows that the majority of participants in the SECuRE study enrolled to date had bone metastasis (77%), high median prostate-specific antigen (PSA) level at baseline (112.86 ng/mL, range 0.1-1503.1) and were heavily pre-treated (59% of participants received 3 or more lines of therapy). Despite how heavily pre-treated these participants were, and how much disease they had, 73% of them across all cohorts (including the lowest dose cohort of 67Cu-SAR-bisPSMA at 4 GBq, single dose) showed reductions in PSA levels. The majority of patients that had an increase in PSA were on the single, lowest dose cohort 1 (4 GBq). PSA reductions of greater than 50% were seen in 45% of all trial participants, despite the overwhelming majority of participants only receiving a single dose of 67Cu-SAR-bisPSMA (4, 8 or 12 GBq) in the trial. In cohorts 2, 3 and 4 (8 and 12 GBq single dose and 12 GBq multi-dose, respectively), in which most participants also only received 1 dose of 67Cu-SAR-bisPSMA, PSA reductions of greater than 35% were observed in almost 75% of participants and PSA was reduced by 80% or more in almost half of the participants so far, as patients continue in follow-up.

The trial is currently progressing through the highest dose cohort where participants were administered multiple doses of 12 GBq of 67Cu-SAR-bisPSMA. Recruitment into cohort 4 is complete, and the remaining 3 participants are currently in the safety and efficacy follow-up period after receiving their first 2 doses. Following completion of the follow-up up period, the safety review committee meeting is planned for March 2025. The largest drop in prostate-specific antigen (PSA) in cohort 4 to date is a decline of 98% (from a baseline of 157.4 ng/mL). This participant, who had failed multiple lines of therapy prior to receiving 67Cu-SAR-bisPSMA (androgen deprivation therapy [ADT], ARPI and an investigational agent), has already had a radiographic partial response based on the investigator’s assessment of Response Evaluation Criteria in Solid Tumours v1.1 (RECIST) criteria. Preliminary analysis showed a reduction of 60.6% in tumour volume evaluated by PSMA positron emission tomography [PET] imaging with 64Cu-SAR-bisPSMA.

Cohort expansion of the SECuRE trial to assess the combination of 67Cu-SAR-bisPSMA with enzalutamide

For a long time, Clarity has been working closely with many important global medical experts in the field of prostate cancer, including the Company’s Clinical Advisory Board members, Prof Louise Emmett and Prof Oliver Sartor, to optimise the development of all of its products in prostate cancer. Those discussions have led to a recent protocol amendment for the SECuRE trial, which aims to investigate ways to further improve the treatment outcomes for these patients. The protocol amendment is aligned with the positive results of the Enza-p trial presented by Prof Emmett first at the European Society for Medical Oncology in 2023[5] and more recently at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium in 2025[6], which confirmed the hypothesis that targeting both androgen signalling and PSMA receptors concurrently would improve anti-cancer activity in mCRPC. The latest SECuRE protocol amendment increased the number of participants in the cohort expansion phase from 14 to 24 patients in the mCRPC pre-chemotherapy setting, with a subset of patients to receive the combination therapy of 67Cu-SAR-bisPSMA with enzalutamide. This protocol amendment has now been approved at many of the participating trial sites, and the changes are expected to further enhance the already positive results of 67Cu-SAR-bisPSMA observed in the SECuRE trial to date. This strategy focuses on the commercialisation of the product firstly in the largest market for prostate cancer therapies in mCRPC, with pre-chemotherapy being 3 times larger than the post-chemotherapy setting, and creates opportunities for the use of 67Cu-SAR-bisPSMA with a range of ARPIs in future clinical development. Addressing the radiopharmaceuticals supply issues with current treatments in such a large indication requires a streamlined approach for which Clarity’s 64Cu/67Cu platform is well and uniquely suited.

Clarity’s Executive Chairperson, Dr Alan Taylor, commented, “Receiving 3 FTDs for the one molecule, SAR-bisPSMA, within the last 6 months is an incredible achievement for Clarity, highlighting how impressive our science and development are, the significance of the diagnostic and therapeutic data so far, and the high unmet need for better therapies and diagnostics in prostate cancer.

“The dual-targeted bisPSMA molecule was developed at the benchtop of Australian science with the intent of overcoming the shortfalls of the current generation of PSMA-targeting products. It was optimised with two PSMA ligands, which increases not only the amount of product in the lesions, but also how long the product is retained in the lesions over time, making it an ideal candidate for both diagnosis and therapy. The clinical data in both diagnostic and therapeutic indications that we are generating is remarkable, confirming the results that we initially saw in preclinical development. The granting of FTDs by the US FDA for 3 distinct indications in prostate cancer that we are aiming to address with this product is testament to the incredible work of our team and collaborators. This latest FTD will allow us flexibility to develop 67Cu-SAR-bisPSMA in both pre- and post-chemotherapy patients in the mCRPC setting, with initial focus on the largest market segment. The SECuRE study will also provide invaluable information on the potential of 67Cu-SAR-bisPSMA to be combined with enzalutamide and other ARPIs in future, creating opportunities for the broader use of 67Cu-SAR-bisPSMA in those patients with such high unmet medical need.

“These designations will allow us to work closely with the FDA to facilitate the development process and accelerate the approval of what could become best-in-class therapy and diagnostic agents, and our team and collaborators are committed to making this our priority in order to achieve our ultimate goal of improving treatment outcomes for people with cancer.”

About SAR-bisPSMA

SAR-bisPSMA derives its name from the word “bis”, which reflects a novel approach of connecting two PSMA-targeting agents to Clarity’s proprietary sarcophagine (SAR) technology that securely holds copper isotopes inside a cage-like structure, called a chelator. Unlike other commercially available chelators, the SAR technology prevents copper leakage into the body. SAR-bisPSMA is a Targeted Copper Theranostic (TCT) that can be used with isotopes of copper-64 (Cu-64 or 64Cu) for imaging and copper-67 (Cu-67 or 67Cu) for therapy.

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA are unregistered products. The safety and efficacy of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA have not been assessed by health authorities such as the US—– FDA or the Therapeutic Goods Administration (TGA). There is no guarantee that these products will become commercially available.

About the SECuRE trial

SECuRE (NCT04868604)[4] is a Phase I/IIa theranostic trial for identification and treatment of an advanced form of prostate cancer, mCRPC. It is a multi-centre, single arm, dose escalation study with a cohort expansion. The aim of this trial is to determine the safety and tolerability of both 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA, as well as the efficacy of 67Cu-SAR-bisPSMA as a therapy. A recent protocol amendment has increased the number of participants in the cohort expansion phase from 14 to 24, and a subset of participants will receive the combination of 67Cu-SAR-bisPSMA with enzalutamide.

About Prostate Cancer

Prostate cancer is the second most common cancer diagnosed in men globally and the fifth leading cause of cancer death in men worldwide[7]. Prostate cancer is the second-leading causes of cancer death in American men. The American Cancer Institute estimates in 2025 there will be about 313,780 new cases of prostate cancer in the U.S. and around 35,770 deaths from the disease[8].

About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious diseases. The Company is a leader in innovative radiopharmaceuticals, developing Targeted Copper Theranostics based on its SAR Technology Platform for the treatment of cancers in children and adults.
www.claritypharmaceuticals.com

For more information, please contact:

Clarity Pharmaceuticals

Dr Alan Taylor    

Catherine Strong

Executive Chairperson     

Investor/Media Relations

ataylor@claritypharm.com        

c.strong@morrowsodali.com 

+61 406 759 268

References

1.  Clarity Pharmaceuticals. Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA. https://www.claritypharmaceuticals.com/news/fast-track/ 

2.  Clarity Pharmaceuticals. Clarity receives U.S. FDA Fast Track Designation for 64Cu-SAR-bisPSMA in biochemical recurrence of prostate cancer. https://www.claritypharmaceuticals.com/news/ftd-2/ 

3.  ClinicalTrials.gov Identifier: NCT06056830, https://clinicaltrials.gov/study/NCT06056830

4.  ClinicalTrials.gov Identifier: NCT04868604, https://clinicaltrials.gov/ct2/show/NCT04868604

5.  Emmett et al. Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Annals of Oncology, Volume 34, S1325, 2023.

6.  Emmett et al. Overall survival and quality of life with [177Lu] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in poor-risk, metastatic, castration-resistant prostate cancer in ENZA-p (ANZUP 1901). American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) Symposium, 2025

7.  Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries, https://acsjournals.onlinelibrary.wiley.com/doi/10.3322/caac.21834

8.  American Cancer Society: Key Statistics for Prostate Cancer, https://www.cancer.org/cancer/prostate-cancer/about/key-statistics.html

This announcement has been authorised for release by the Executive Chairperson.

Flying Cars Are Here: Alef flies a car in a city

Alef conducted the first test in history of a car drive and vertical takeoff in a city

  • Alef car flew over another car to test an emergency blocking traffic situation
  • An ultralight version of Alef Aeronautics flying car was tested by flying over a closed-off city road in a non-densely populated area
  • The public street was closed off, no bystanders were under or near the flight path, and the surrounding area was non-densely populated

SANTA MATEO, Calif., Feb. 19, 2025 /PRNewswire/ — Alef Aeronautics, a sustainable mobility company designing and developing a flying car, announced today that it successfully conducted a flight test of its flying car in a city environment.

What is the historical significance of this? Alef released the video of the test, making it a first-ever video in history of a car driving and vertically taking off. While previous videos exist of cars driving and using a runway to take off, videos of tethered flights, and eVTOL flying taxis taking off, this is the first publicly released video of a car driving and taking off vertically.

The test was conducted with thorough safety measures, ensuring the road was closed off during the flight test, no people were under or near the flight path, the area around was not densely populated, and all safety equipment and personnel were present. The test was completed successfully without any safety issues.

A special ultralight version of the Alef Model Zero was used. In the past year, Alef achieved both a reduction in weight and enhancements in structural integrity.

“This drive and flight test represents an important proof of technology in a real-world city environment. We hope it will be a moment similar to the Wright Brothers’ Kitty Hawk video, proving to humanity that new transportation is possible,” said Jim Dukhovny, CEO of Alef.

Alef’s flying car is 100% electric, drivable on public roads, and has vertical takeoff and landing capabilities. Alef received 3,330 pre-orders through its website: https://alef.aero.

About Alef

Alef, based in San Mateo, CA, is a sustainable electric transportation company designing and developing a road-legal passenger car capable of vertical takeoff and forward flight. More information can be found at https://alef.aero.

Media Contact: press@alef.aero
Videos and Photos in Press Kit: https://alef.aero/press.html

 

Alef_Aeronautics

 

 

Alef Aeronautics flying car driving off-road

 

Jim Dukhovny CEO of Alef near the flying car during a flight test
Jim Dukhovny CEO of Alef near the flying car during a flight test

Deloitte and CAS publish new report analyzing the lithium-ion battery recycling industry amid growing demand for sustainable energy solutions

The report explores policy, market, and innovation trends shaping this rapidly expanding industry

HONG KONG and COLUMBUS, Ohio, Feb. 19, 2025 /PRNewswire/ — Deloitte and CAS, a division of the American Chemical Society specializing in scientific knowledge management, announced today the release of a collaborative report, Lithium-Ion Battery Recycling: Market & Innovation Trends for A Green Future. This report is the first shared project between the two organizations since their strategic collaboration announcement last year.

Lithium-ion battery recycling report available now
Lithium-ion battery recycling report available now

Growing demand for electric vehicles, renewable energy storage, and consumer electronics is driving an urgent focus on sustainable battery recycling solutions. The report by CAS and Deloitte is a comprehensive analysis of lithium-ion battery recycling and covers both market and scientific perspectives on this rapidly evolving industry. It includes insights into the market dynamics, technological advances, and strategic pathways to profitability in the sector and highlights the key role of battery recycling in addressing resource scarcity and environmental challenges amid growing demand for sustainable energy solutions.

Lithium-Ion Battery Recycling: Market & Innovation Trends for A Green Future combines the CAS unparalleled data and scientific expertise with Deloitte’s market and business analysis to explore the latest developments in the industry across six key dimensions: policy, capacity expansion, technological innovation, digital solutions, cross-sector collaboration, and pathway to profitability. Among other trends, the report explores how recycling technology innovation and digital solutions are transforming the battery recycling industry, driving improvements in efficiency, recovery rates, and environmental impact and accelerating the global transition to a low-carbon future.

“We are pleased to develop and provide industry insights and solutions based on CAS scientific data,” says Kevin Guo, Deloitte China National Industry Program leader. “Science and technology innovations have made remarkable progress in multiple fields, and Deloitte China looks forward to continuing to work with CAS to make a significant impact on the industry.”

“This in-depth report showcases the powerful synergy of Deloitte’s market insights and CAS unmatched scientific data and technical expertise. Through this collaboration, together we aim to accelerate breakthroughs on critical global challenges, such as sustainable energy, and enable innovators across industries to make more confident business decisions,” said Manuel Guzman, President of CAS.

The report is now available for download at link.cas.org/li-battery-report.

About CAS
CAS connects the world’s scientific knowledge to accelerate breakthroughs that improve lives. We empower global innovators to efficiently navigate today’s complex data landscape and make confident decisions in each phase of the innovation journey. As a specialist in scientific knowledge management, our team builds the largest authoritative collection of human-curated scientific data in the world and provides essential information solutions, services, and expertise. Scientists, patent professionals, and business leaders across industries rely on CAS to help them uncover opportunities, mitigate risks, and unlock shared knowledge so they can get from inspiration to innovation faster. CAS is a division of the American Chemical Society. Connect with us at cas.org.

About Deloitte China

Deloitte China provides integrated professional services, with our long-term commitment to be a leading contributor to China’s reform, opening-up and economic development. We are a globally connected firm with deep roots locally, owned by our partners in China. With over 20,000 professionals across 31 Chinese cities, we provide our clients with a one-stop shop offering world-leading audit, tax and consulting services.

We serve with integrity, uphold quality and strive to innovate. With our professional excellence, insight across industries, and intelligent technology solutions, we help clients and partners from many sectors seize opportunities, tackle challenges and attain world-class, high-quality development goals.

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 19TH + NIKE ANNOUNCES COLLABORATION WITH SKIMS

NEW YORK, Feb. 19, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) is proud to offer a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

 

NYSE CONTENT ADVISORY: PRE-MARKET UPDATE FOR FEBRUARY 19TH + NIKE ANNOUNCES COLLABORATION WITH SKIMS

Trinity Chavez delivers the pre-market update on February 19th

  • Nike (NYSE: NKE) and Skims introduce new brand for women: NikeSKIMS
  • Investors anticipate speech from Fed Vice Chair Philip Jefferson
  • Key housing data to publish, including housing starts and building permits

Watch NYSE TV Live every weekday 9:00-10:00am ET 

 

Ace Green Recycling Secures Key Lead and Lithium Licensing Agreements in Armenia

Deals support Ace’s broader strategy to generate revenues in a capital efficient manner

Deployment in Armenia serves as springboard for Ace’s recycling solutions to expand in the Southern Caucasus and as a gateway to additional expansion in Europe

HOUSTON, Feb. 19, 2025 /PRNewswire/ — Ace Green Recycling, Inc. (“Ace” or the “Company”), a leading provider of sustainable battery recycling technology solutions, today announced the Company has signed two key agreements to license its technology and battery recycling equipment to Mel Metal LLC (“Mel Metal”), a leading Armenian non-ferrous scrap recycling company. As part of these deals, Ace expects to license its proprietary GREENLEAD® Recovery Technology and sell and license its lithium battery equipment services to Mel Metal in Armenia and Georgia.

Armenia is a strategic location for Ace as it sits at the heart of the Southern Caucasus and Ace believes it can provide a springboard for the Company to deploy its sustainable battery recycling solutions into neighboring Georgia. In addition, Armenia serves as a gateway to critical European markets. Through this collaboration, Ace plans to establish the foundation of environmentally friendly lead and lithium battery recycling, with strong commercial partnerships, to support the growth of the region’s lead and lithium battery value chain.

As part of the lead battery recycling aspect of the deal, Ace will license its technology for the sustainable, hydrometallurgical recycling of lead batteries over a 15-year period. Mel Metal will purchase lead battery recycling machinery from Ace that will allow it to process up to 6,000 metric tons of lead batteries per year with the option to acquire more recycling capacity. In addition, Ace will generate revenue by selling and supplying proprietary chemicals and enabling the use of Ace’s GREENLEAD® trademark. Mel Metal’s lead recycling operations using Ace’s technology are expected to start in the third quarter of 2025.

In addition to the lead agreement, Ace will sell and license its lithium battery breaking and shredding equipment and battery discharging system to support Mel Metal’s lithium battery recycling operations. Mel Metal’s lithium battery recycling operations using Ace’s equipment and system are also expected to start in the third quarter of 2025.

“Ace is an innovative and global technology leader in the battery recycling space, and we look forward to partnering with them to support a more circular battery material ecosystem in the Southern Caucasus,” said Mr. Armen Hayrapetyan, Chairman of the Edmet group of companies, which is the parent company of Mel Metal. “Unlike traditional smelting processes, Ace’s hydrometallurgical battery recycling processes emit zero Scope I carbon emissions. By leveraging Ace’s technology, equipment, and know-how, Mel Metal is actively supporting a green transition by reducing CO2 emissions and developing a clean source of valuable materials for reuse in new batteries. Furthermore, Ace’s process also allows for the recovery of plastics and reduces the generation of slag materials into landfills.”

“We are proud to partner with Mel Metal, a first mover in green recycling in Armenia, as together we are playing a crucial role in developing a sustainable, domestic battery recycling ecosystem in Armenia and the broader Southern Caucasus region,” said Nishchay Chadha, CEO and Co-Founder of Ace. “Without Ace’s technology and equipment in Armenia, scrap battery material would likely be exported or undergo a pollutive pyrometallurgical material recovery process. Securing both these lead and lithium agreements supports Ace’s broader strategy to generate revenues in a capital efficient manner while we deploy our modular and sustainable recycling solutions globally.”

About Ace Green Recycling

Ace Green Recycling, Inc., incorporated in Delaware, is an innovative battery recycling technology platform offering sustainable end-of-life solutions. It has deployed modular, Scope 1 carbon emissions-free recycling facilities for lithium (nickel-manganese-cobalt & lithium iron phosphate) and lead batteries used in various industries including electronics, automotive and energy storage. Ace was founded by Nishchay Chadha, Chief Executive Officer and a veteran in recycling, mining and global supply chain industries, and Dr. Vipin Tyagi, Chief Technology Officer, with extensive experience in battery materials recycling technologies. For more information, please visit www.acegreenrecycling.com.

Contacts:

Media
Media@acegreenrecycling.com

Investors
Investors@acegreenrecycling.com

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements generally can be identified by the use of words such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. Such statements include statements regarding the intent, belief or current expectations of Ace and members of its management as well as the assumptions on which such statements are based. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties that could cause actual events or results to vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance. Forward-looking statements contained in this press release are made as of this date, and Ace undertakes no duty to update such information except as required under applicable law.